STOCK TITAN

Repligen (RGEN) CFO stock withheld to cover RSU tax obligations

Filing Impact
(High)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Repligen Corporation’s CFO Jason K. Garland reported routine tax-related share withholdings. On March 2, 2026, the company withheld 715 shares of common stock at $124.97 per share, and on February 27, 2026, it withheld 327 shares at $128.73 per share to satisfy tax obligations triggered by restricted stock unit releases. These dispositions were for tax withholding rather than open-market sales.

Positive

  • None.

Negative

  • None.
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Garland Jason K

(Last) (First) (Middle)
C/O REPLIGEN CORPORATION
41 SEYON ST., BLDG 1, STE 100

(Street)
WALTHAM MA 02453

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
REPLIGEN CORP [ RGEN ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
CFO
3. Date of Earliest Transaction (Month/Day/Year)
02/27/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 02/27/2026 F 327(1) D $128.73 13,056 D
Common Stock 03/02/2026 F 715(1) D $124.97 12,341 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Represents the number of shares withheld by the Issuer to satisfy tax withholding obligations of the reporting person that arose upon the release of restricted stock units.
/s/ Jennifer Carmichael (Attorney in Fact) 03/03/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did Repligen (RGEN) CFO Jason K. Garland report?

Repligen CFO Jason K. Garland reported two tax-related share dispositions. The issuer withheld 715 shares and 327 shares of common stock to cover tax obligations arising from restricted stock unit releases, rather than Garland executing open-market sales of shares.

Were the recent Repligen (RGEN) insider transactions open-market stock sales?

The reported Repligen insider transactions were not open-market stock sales. Shares were withheld by the company to satisfy Jason K. Garland’s tax obligations upon restricted stock unit vesting, a standard administrative mechanism instead of discretionary buying or selling in the market.

How many Repligen (RGEN) shares were withheld for the CFO’s taxes and at what prices?

Repligen withheld 715 common shares at $124.97 each on March 2, 2026, and 327 common shares at $128.73 each on February 27, 2026, to cover CFO Jason K. Garland’s tax liabilities from restricted stock unit releases.

What does transaction code "F" mean in the Repligen (RGEN) Form 4 filing?

Transaction code “F” in the Repligen Form 4 indicates a tax-withholding disposition. It reflects payment of exercise price or tax liability by delivering securities, rather than a voluntary open-market sale initiated by the insider for investment or portfolio reasons.

Does the Repligen (RGEN) Form 4 show the CFO buying any shares?

The Form 4 for Repligen shows no insider share purchases by the CFO. It only reports two “F” code transactions, which are share withholdings by the issuer to satisfy tax obligations when restricted stock units were released.
Repligen

NASDAQ:RGEN

RGEN Rankings

RGEN Latest News

RGEN Latest SEC Filings

RGEN Stock Data

6.93B
52.58M
Medical Instruments & Supplies
Biological Products, (no Diagnostic Substances)
Link
United States
WALTHAM